LIXTE Biotechnology Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative) - USD ($)								2 Months Ended	3 Months Ended
	Apr. 09, 2021	Aug. 12, 2020	Sep. 12, 2018	Aug. 20, 2018	Mar. 22, 2018	Sep. 14, 2015	Dec. 24, 2013	Aug. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Loss Contingencies [Line Items]
Contractual commitment									$ 8,399,000
Research and development costs									458,450	$ 443,526
City of Hope [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected									307,000
GEIS [Member]
Loss Contingencies [Line Items]
Amount related to milestone payment									67,582
NDA Consulting Corp [Member]
Loss Contingencies [Line Items]
Consulting and advisory fee							$ 4,000		4,000	4,000
Clinical Trial Research Agreement [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment									3,332	7,384
Research and development costs									$ 108,009
Aggregate commitments expected, description									The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $600,000 as of March 31, 2022, which is expected to be incurred through December 31, 2025
Aggregate commitments expected									$ 600,000
Collaboration Agreement [Member] \| GEIS [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment									0	24,171
Research and development costs									$ 155,053
Aggregate commitments expected, description									The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $4,166,000 as of March 31, 2022, which is expected to be incurred through December 31, 2025
Aggregate commitments expected									$ 4,166,000
Collaboration Agreement [Member] \| BioPharmaWorks LLC [Member]
Loss Contingencies [Line Items]
Consulting and advisory fee						$ 10,000
Reimbursed expense									30,000	30,000
Development Agreement [Member]
Loss Contingencies [Line Items]
Research and development costs									$ 292,293
Aggregate commitments expected, description									The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $29,000 as of March 31, 2022, which is expected to be incurred through June 30, 2022
Aggregate commitments expected									$ 29,000
Other Clinical Agreements [Member]
Loss Contingencies [Line Items]
Research and development costs									1,153,000
Aggregate commitments expected									206,000
Clinical Research Support Agreement [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected									800,000
Clinical Research Support Agreement [Member] \| City of Hope [Member]
Loss Contingencies [Line Items]
Research and development costs									0	240,508
Aggregate commitments expected									2,433,000
Work Order Agreement [Member]
Loss Contingencies [Line Items]
Research and development costs									95,166
Aggregate commitments expected									864,000
Work Order Agreement [Member] \| City of Hope [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment									4,500	3,540
Aggregate commitments expected									29,126
Work Order Agreement [Member] \| Theradex Systems, Inc. [Member]
Loss Contingencies [Line Items]
Research and development costs			$ 954,000						3,281	941
Material Transfer Agreement [Member] \| INSERM [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected									0		$ 0
Material Transfer Agreement [Member] \| INSERM [Member] \| Development Milestones [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Milestone payments					$ 1,750,000
Material Transfer Agreement [Member] \| INSERM [Member] \| Commercial Milestones [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Milestone payments					$ 6,500,000
Exclusive License Agreement [Member] \| First Four Years [Member]
Loss Contingencies [Line Items]
Minimum payments for royalties									50,000
Exclusive License Agreement [Member] \| Five Years And Thereafter [Member]
Loss Contingencies [Line Items]
Minimum payments for royalties									100,000
Exclusive License Agreement [Member] \| Moffitt Cancer Center and Research Institute Hospital Inc [Member]
Loss Contingencies [Line Items]
Non-refundable license issue fee				$ 25,000
Annual license maintenance fee				25,000
Payments on non-refundable milestone				$ 1,897,000
Amount charges to operations									6,165	$ 6,164
Employment Agreement [Member] \| Executive Officers [Member]
Loss Contingencies [Line Items]
Salary and Wage, Excluding Cost of Good and Service Sold								$ 640,000
Agreement term description								one-year period
Employment Agreement [Member] \| Dr.James [Member]
Loss Contingencies [Line Items]
Annual compensation	$ 775,000
Master Service Agreement [Member] \| Foundation for Angelman Syndrome Therapy [Member]
Loss Contingencies [Line Items]
Percentage of proceeds agree to pay under agreement		5.00%
Maximum amount received under agreement		$ 250,000
Development Collaboration Agreement [Member] \| Netherlands Cancer Institute [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment									54,230
Research and development costs									$ 109,478
Aggregate commitments expected, description									The Company’s aggregate commitment pursuant to this collaboration agreement, less amounts previously paid to date, totaled approximately $380,000 as of March 31, 2022, which is expected to be incurred through June 30, 2025
Aggregate commitments expected									$ 380,000